ClinicalTrials.govpublic full text
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024
immunocompromised patients, sars-cov-2 disease, mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 905171
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.